New research reveals that patients who discontinue new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle programs.
Published data in a prominent health publication demonstrates that while obese individuals can lose about a fifth of their total mass while using the jabs, the weight returns at an average rate of nearly a kilo each month once they quit.
"People using these medications should be informed of the risk of rapid rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
Such speed of regain suggests a return to original mass within about 18 months.
Comparing Therapies
The study, which looked at 37 of studies involving over 9,000 of patients, contrasted the effects of these new drugs with conventional dieting.
Scientists point out that people who lose weight through lifestyle changes alone typically experience a more gradual weight regain—around 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Doctors propose the mode of action of the jabs is key to understanding the heightened regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of the hormone concentrations far above than the body's typical production may cause the body to produce less of its own natural hormone, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making binge eating a significant risk."
An Ongoing Condition?
The NHS suggest the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, given the likelihood of relapse, the therapy should be considered life-long.
This view is reinforced by drug manufacturers, who state that the findings "highlight the long-term character of obesity," similar to managing diseases like high blood pressure.
User Experiences
Individuals who have come off the jabs describe a powerful resurgence of hunger.
"It was like something flipping and you're instantly extremely hungry," described one woman.
This difficulty is worsened if users have not established permanent dietary or behavioural changes during therapy.
Significant Use
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is greater among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on integrated behavioural support.
